Abstract
Nitric oxide (NO) and endothelin-1 (ET-1) are two substances that take part in the regulation of vascular smooth muscle tone. ET-1 is a vasoconstrictor peptide and NO is a vasodilating molecule. There have been contradictory reports of the plasma levels of these substances in patients with chronic renal failure (CRF). We studied plasma levels of ET-1 and NO in hypertensive and normotensive patients with CRF either on dialysis or on non-dialysis treatment. A total of 41 patients were studied, 23 males and 18 females with mean age of 50.39±14.46 years. The control group consisted of healthy subjects (22 males and 8 females) with a mean age of 46.50±8.21 years. The plasma levels of ET-1 were significantly higher and NO levels were lower in the CRF patients than in controls (p<0.05). The plasma levels of NO were lower in patients hypertensive CRF than in normotensive CRF patients (p<0.05). Plasma ET-1 levels, however, did not show any difference (p<0.05). However, plasma NO levels were lower in patients on haemodialysis than in patients on non-dialysis conservative treatment (p<0.01). Except for the negative correlation between the plasma NO and creatinine levels (p<0.01), there were not any relationship between the plasma NO and ET-1 levels, renal function tests (BUN, creatinine), duration of disease and haemodialysis.
We concluded that hypertension in CRF has a multifactorial aetiology and that decrease of NO levels, and disturbance of the balance between NO and ET-1 levels might be more important than the above factors alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., Masaki, T.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411 (1988).
Kohan, E. D.: Endothelins in the normal and diseased kidney. Am. J. Kidney Dis., 1, 2 (1997).
Davenport, A. P., Ashby, M. J., Easton, P., Ella, S., Bedford, J., Dickerson, C., Nunez, D. J., Capper, S. J., Brown, M. J.: A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin. Sci., 78, 261 (1990).
Kohno, M., Murakawa, K. I., Horio, T., Yakokawa, K., Yasunari, K., Fukui, T., Takeda, T.: Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension, 18, 93 (1991).
Moncada, S., Palmer, R. M., Higgs, E. A.: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43, 109 (1991).
Lahera, V., Navarro, C., Cachoferio, V., Garcia-Estan, J., Ruilope, L. M.: Nitric oxide, the kidney, and hypertension. Am. J. Hypertens., 10, 129 (1997).
Deray, G., Carayon, A., Maistre, G., Benhmida, M., Masson, F., Borthelemy, C., Petitclerc, T., Jacobs, C.: Endothelin and chronic renal failure. Nephrol. Dial. Transplant., 7, 300 (1992).
Lyall, F., Young, A., Greer, I. A.: Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Am. J. Obstet. Gynecol., 73, 714 (1995).
Horio, T., Fukui, T., Takeda, T.: Plasma immunoreactive endothelin in essential hypertension. Am. J. Med., 18, 93 (1991).
Lerman, A., Edwards, B. S., Hallett, J. W., Heublein, D. M., Sandberg, S. M., Burnett, J. C. J.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med., 325, 997 (1991).
Bolger, G. T., Liard, F., Jodoin, A., Jaramillo, J.: Vascular reactivity, tissue levels, and binding sites for endothelin: A comparison in the spontaneously hypertensive and Wistar-Kyoto rats. Can. J. Physiol. Pharmacol., 69, 406 (1991).
Clozel, M.: Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J. Hypertens., 7, 913 (1989).
Goligorsky, M. S., Iijima, K., Morgan, M., Yanagisawa, M., Masaki, T., Lin, L., Nasjletti, A., Kaskel, F., Frazer, M., Badr, K. F.: Role of endothelin in the development of Dahl hypertension. J. Cardiovasc. Pharmacol. (Suppl. 7), 17, 484 (1991).
Ohno, A., Naruse, M., Kato, S., Hosaka, M., Karuse, K., Demura, H., Sugino, N.: Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J. Hypertens., 10, 781 (1992).
Vallance, P., Leone, A., Calver, A., Collier, J., Moncada, S.: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339, 572 (1992).
Baylis, C., Bloch, J.: Nitric oxide (NO) in renal physiology and pathophysiology. Nephrol. Dial. Transplant., 11, 1955 (1996).
Thorup, C., Persson, G. E. A.: Nitric oxide and renal blood pressure regulation. Current. Opinion in Nephrology and Hypertension, 7, 197 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cengiz, K., Gören, I. & Amanvermez, R. Nitric Oxide and Endothelin-1 in Chronic Renal Failure. Int Urol Nephrol 31, 845–850 (1999). https://doi.org/10.1023/A:1007170218824
Issue Date:
DOI: https://doi.org/10.1023/A:1007170218824